Home

AbVision > Home

Our Company

AbVision, Inc. (AVI) previously the Drug Discovery Group of BioVision Inc., is a privately held biopharmaceutical company headquartered in Reno Nevada with a R&D facility in San Jose California.  AVI’s most advanced drug discovery efforts aim to develop therapeutics for cancer and infectious disease that harness the natural power of the immune system to bring first-in-class and best-in-class drugs to benefit human health.

Our Science

AbVision brings significant experience and innovation in cancer immunotherapy and infectious diseases. The company’s technology platforms provide a great value on antibody discovery, vaccine and cell therapy. We are using the advanced knowledge and emerging technology to speedily develop the next generation of biologics that substantially enhance tumor or pathogen-specific immune response to fight cancer and infection.

Our Technology

Therapeutic Antibody

SpeedyAb™ technology platform provides high-throughput features of antibody screening for obtaining the therapeutic leads with high affinity and broad diversity.

Vaccine

ImmunoBuster I+II™ technology platform develops one-shot vaccines with strong immunogenicity for prophylactic and therapeutic treatment without additional boost. An immunological module for eliciting quick yet rebust immunity and is comparable with commercially available vaccine.

Cell Therapy

TsKill™ technology platform enables low frequency of tumor-specific T cells to effectively destroy tumors by enhancing the functionality of effector cells and tumor recognition.

Targeted Therapy

OctopusLink™ belongs to an emerging class of antibody targeted therapy against cancer, which allows for a targeted delivery of cytotoxic payloads to malignant cells. Highly potent drugs are conjugated to antibodies with linkers, and ADC needs to remain stable in circulation yet rapidly releases its drugs upon internalization into the targeted cells.

Read More

Pipeline

Immuno-oncology

AVI - 101 - Preclinical
AVI - 102 - Preclinical
AVI - 103 - Preclinical
AVI - 104 - Early Discovery
AVI - 105 - Preclinical

Vaccine

AVI - 201 - Preclinical
AVI - 205 - Preclinical

Cell Therapy

AVI - 301 - Preclinical

Targeted Therapy

AVI - 801 - Preclinical
§ AVI-102 (Anti-human PD-1 ICB antibody), AVI-103 (Anti-human CTLA-4 ICB antibody), AVI-105 (Anti-human CD47 ICB antibody) and AVI-205 (COVID-19 Active Targeting Vaccine) are available for out-licensing to enable faster downstream development and clinical studies.